A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of Zostavax in Subjects 50-59 Years of Age.

Trial Profile

A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of Zostavax in Subjects 50-59 Years of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary)
  • Indications Herpes zoster
  • Focus Registrational; Therapeutic Use
  • Acronyms ZEST
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Apr 2016 Results (post hoc pooled analysis of this and other study, n = 28785) assessing severe injection-site and systemic AEs presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases.
    • 09 Feb 2012 Results published in Clinical Infectious Diseases.
    • 09 Feb 2012 Primary endpoint 'Disease-occurrence-rate' has been met, according to results published in Clinical Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top